Bausch+Lomb Results Presentation Deck
FY22 Financial Highlights & Segment Drivers
Total Company Revenue
Millions USD
●
3,765
184
3,581
FY21
FX Impact³
3,768
FY22
+5%
organic revenue ¹,2 growth
Second consecutive full year of organic
revenue growth 1,2
BAUSCH + LOMB
China continued to impact top line
(~150bps) during FY22 as country's
COVID conditions and policies evolved
FX conditions during FY22 impacted
business by $184M
63%
Vision Care
$2,373M
Consumer
37%
Contact Lens
FY 22
Surgical
+6%
Strong demand for key franchises:
Lumify® (+21% reported revenue growth)
. Ocuvite® + PreserVision® (+10% reported
revenue growth)
Daily SiHy (+46% reported revenue growth)
Bausch+Lomb ULTRA® (+4% reported revenue
growth)
• Bio True ONEday (+4% reported revenue growth)
53% $718M
27%
20%
■ Implantables ■ Equipment
Consumables/Other
ORGANIC REVENUE
+8%
Growth in implantables (+4% reported revenue
growth; +12% organic revenue growth ¹.2)
Strong demand for consumables (2% reported
revenue growth; 9% organic revenue growth ¹.2)
LuxSmartTM launched in 19 countries in Europe
and 10 additional countries expected in 2023
• Expansion of the portfolio with AcuFocus
acquisition, using cash on hand, in early 2023
.
.
Ophthalmic
Pharmaceuticals
60%
$677M
U.S.
CHANGE
40%
International
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. FX impact is determined by comparing 2022 reported amounts adjusted to exclude currency impact, calculated using 2021 monthly average exchange rates, to the actual 2021 reported amounts.
1, 2
+0%
Strong performance in international portfolio (2%
reported revenue decline; 7% organic revenue
growth 1,2)
Vyzulta: 31% reported revenue growth vs. FY21;
geo-expansion continuing in 2023
Positive early stages of XIPEREⓇ U.S. launch
NOV03 PDUFA date June 28, 2023; expect
Canada filing in 1Q23
10View entire presentation